Edition:
United Kingdom

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

48.31USD
5:45pm BST
Change (% chg)

$0.19 (+0.39%)
Prev Close
$48.12
Open
$48.09
Day's High
$49.32
Day's Low
$47.51
Volume
69,148
Avg. Vol
349,021
52-wk High
$82.68
52-wk Low
$33.06

Latest Key Developments (Source: Significant Developments)

Esperion Posts Qtrly Loss Per Share $1.73
Wednesday, 2 May 2018 

May 2 (Reuters) - Esperion Therapeutics Inc ::ESPERION PROVIDES BEMPEDOIC ACID FRANCHISE DEVELOPMENT PROGRAM UPDATES; REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.ESPERION THERAPEUTICS INC - EXPECTS FULL-YEAR 2018 NET CASH USED IN OPERATING ACTIVITIES TO BE APPROXIMATELY $135 TO $145 MILLION.ESPERION THERAPEUTICS - ESTIMATES THAT CURRENT CASH RESOURCES ARE SUFFICIENT TO FUND OPERATIONS THROUGH Q1 OF 2020.ESPERION THERAPEUTICS INC - EXPECTS CASH AND CASH EQUIVALENTS AND INVESTMENT SECURITIES TO BE APPROXIMATELY $130 TO $140 MILLION AT DECEMBER 31, 2018.ESPERION THERAPEUTICS INC QTRLY LOSS PER SHARE $1.73.  Full Article

Esperion Says Phase 3 Long-Term Safety Study Of Bempedoic Acid Met Primary Endpoint
Wednesday, 2 May 2018 

May 2 (Reuters) - Esperion Therapeutics Inc ::ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 LONG-TERM SAFETY STUDY OF BEMPEDOIC ACID.ESPERION THERAPEUTICS INC - STUDY MET PRIMARY ENDPOINT OF SAFETY AND TOLERABILITY IN LARGEST AND LONGEST DURATION STUDY.ESPERION - PATIENTS TREATED WITH BEMPEDOIC ACID ALSO ACHIEVED A SIGNIFICANT REDUCTION OF 22 PERCENT IN HIGH-SENSITIVITY C-REACTIVE PROTEIN.  Full Article

Esperion Announces Positive Top-Line Results From Phase 2 Study Of Bempedoic Acid Added-On To A PCSK9 Inhibitor
Tuesday, 27 Mar 2018 

March 27 (Reuters) - Esperion Therapeutics Inc ::ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 STUDY OF BEMPEDOIC ACID ADDED-ON TO A PCSK9 INHIBITOR IN PATIENTS WITH HYPERCHOLESTEROLEMIA.ESPERION THERAPEUTICS INC - STUDY MET PRIMARY ENDPOINT WITH 30% ADDITIONAL LDL-C LOWERING.ESPERION THERAPEUTICS INC - BEMPEDOIC ACID ADDED-ON TO A PCSK9 INHIBITOR OBSERVED TO BE SAFE AND WELL-TOLERATED IN THIS STUDY.ESPERION THERAPEUTICS - TO SUBMIT NDAS TO U.S. FDA FOR BEMPEDOIC ACID, BEMPEDOIC ACID/EZETIMIBE COMBINATION PILL FOR LDL-C-LOWERING INDICATIONS BY Q1 2019.  Full Article

Esperion Therapeutics Q3 loss per share $1.86‍​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Esperion Therapeutics Inc :Esperion provides bempedoic acid franchise development program updates; reports third quarter 2017 financial results.Expects full-year 2017 net cash used in operating activities to be approximately $135 million​.Expects cash and cash equivalents and investment securities to be approximately $272 million at December 31.Estimates cash resources are sufficient to fund operations through Q1 2020​.Qtrly loss per share $1.86‍​.Q3 earnings per share view $-1.78 -- Thomson Reuters I/B/E/S.  Full Article

Esperion announces initiation of pivotal late stage study for bempedoic acid
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Esperion Therapeutics Inc :Esperion announces initiation of pivotal late stage study for the bempedoic acid / ezetimibe combination pill.Esperion Therapeutics - ‍NDA submission for LDL-C lowering indication for bempedoic acid / ezetimibe combination pill expected by Q1 2019​.Esperion Therapeutics Inc - ‍top-line results expected by q4 of 2018 for bempedoic acid / ezetimibe combination pill​.  Full Article

Meditor Group Ltd reports 8.2 pct passive stake in Esperion Therapeutics Inc
Monday, 21 Aug 2017 

Aug 21 (Reuters) - Esperion Therapeutics Inc ::Meditor Group Ltd reports 8.2 percent passive stake in Esperion Therapeutics Inc as on Aug 10 - SEC filing​.  Full Article

BB Biotech reports 5.1 pct passive stake in Esperion Therapeutics
Tuesday, 27 Sep 2016 

Esperion Therapeutics Inc :BB Biotech AG reports 5.1 pct passive stake in Esperion Therapeutics as of September 22, 2016 - SEC filing.  Full Article

Esperion's cholesterol drug safe, effective in new late-stage study

May 23 Esperion Therapeutics said on Wednesday its cholesterol drug was safe and effective in treating heart disease patients in a new late-stage study, weeks after data from an earlier trial raised concerns about the treatment's efficacy.